Study Shows that Six Months of Neoadjuvant ADT Significantly Reduces Mortality in Locally Advanced Prostate Cancer

Researchers from the Trans-Tasman Radiation Oncology Group 96.01 trial study (TROG 96.01) concluded that six months of treatment with neoadjuvant androgen deprivation combined with radiation reduced the risk for disease-specific death by 49% in men with locally advanced prostate cancer.

During the period of June 1996 to February 2000, 818 men with T2b, T2c, T3 and T4 N0 M0 prostate cancers randomly receive radiotherapy alone (n=270), 3-month neoadjuvant androgen deprivation therapy (ADT) plus radiotherapy (n=265) or 6-month neoadjuvant ADT plus radiotherapy (n=267). All the men were aged from 41 to 87 years

The men in the experimental arms were assigned to neoadjuvant ADT with once-monthly subcutaneous 3.6 mg goserelin (Zoladex) and thrice-daily oral 250 mg flutamide (Eulexin). Therapy began 2 months before radiation in the 3-month group and 5 months before radiatio